Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Boosted by Eagle Asset Management Inc.

Eagle Asset Management Inc. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 41.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 38,857 shares of the company’s stock after buying an additional 11,401 shares during the quarter. Eagle Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $665,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Charles Schwab Investment Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 24.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company’s stock valued at $16,203,000 after purchasing an additional 177,836 shares during the period. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $439,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $14,840,000. Finally, Factorial Partners LLC boosted its position in Teva Pharmaceutical Industries by 14.3% during the 3rd quarter. Factorial Partners LLC now owns 311,000 shares of the company’s stock worth $5,604,000 after acquiring an additional 39,000 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TEVA shares. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Down 2.5 %

NYSE TEVA opened at $16.69 on Tuesday. The company has a market capitalization of $18.91 billion, a P/E ratio of -19.87, a PEG ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The company’s 50 day simple moving average is $17.67 and its 200 day simple moving average is $17.35.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.